Answers are grounded in this paper and cite their sources.
Case report identifies elobixibat as a cause of ischemic colitis in a woman with ulcerative colitis, suggesting caution in its use.
Here, we present the case of a woman in her 50s who was hospitalized for ulcerative colitis and dyslipidemia. The patient did not have bowel movement for four days; therefore, elobixibat was administered. After 3 h 30 min, crampy abdominal pain occurred, followed by one bowel movement with hard, watery, and bloody stools. Colonoscopy revealed a longitudinal ulcerative lesion with edema in the sigmoid colon, approximately 25 cm from the anal verge. Histopathological analysis of biopsy specimens revealed ischemic loss of crypts and inflammatory cell infiltration compatible with ischemic colitis. Follow-up endoscopy conducted after one month confirmed an ulcer scar in the sigmoid colon. The patient remains under regular follow-up. Several medications, such as irritant laxative, have been implicated in the development of colonic ischemia. To the best of our knowledge, this is the first reported case of ischemic with elobixibat.
No takes yet. Share an insight, caveat, or question.
Kusano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: